Bajaj Healthcare has dispatched letters to physical shareholders containing the web-link to its Annual Report for the financial year ending March 2026. The communication serves as a statutory intimation under SEBI listing regulations.

The company scheduled its 33rd Annual General Meeting for Monday, September 21, 2026, at 3:00 pm. The meeting will be conducted through video conferencing or other audio-visual means, allowing remote participation for all members.

Regulatory Compliance and Shareholder Action

Pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the firm sent these letters specifically to shareholders who have not registered their email addresses with the company or their depository participants as of August 21, 2026.

Shareholders can access the complete Annual Report for FY26 via the company’s website. The document is hosted at a specific path provided in the dispatch letter, ensuring equitable access to financial disclosures for those without digital registration.

KYC and Demat Mandates

The notice reiterates regulatory requirements for updating Know Your Customer (KYC) details. Citing SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024, the company reminded physical security holders to update their PAN, address, mobile number, bank account details, specimen signature, and nomination choices.

Effective April 1, 2024, payments such as dividends or interest for folios lacking updated KYC details are eligible only through electronic mode. Shareholders holding securities in physical form are urged to dematerialise holdings or update details with the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.

Contact Information

All shareholder queries or service requests must be directed to the RTA. MUFG Intime India Private Limited, formerly Link Intime India Private Limited, handles these communications from its Mumbai office. Shareholders are encouraged to register email IDs to facilitate future electronic communications and support green initiatives.

Bajaj Healthcare reported a 12.6% year-on-year rise in revenue to ₹611.03 crore for FY26, driven by strong overseas performance. However, net profit fell 50.4% to ₹213.10 crore due to a significant one-time exceptional loss.

The Mumbai-based pharmaceutical manufacturer held its 33rd Annual General Meeting on September 21, 2026, where shareholders approved the adoption of the audited financial statements for the fiscal year ended March 31, 2026. The Board also recommended a final dividend of ₹1.50 per equity share, representing a 30% payout on the face value of ₹5.

Financial Performance

Revenue from operations grew from ₹542.60 crore in FY25 to ₹611.03 crore in FY26. EBITDA increased by 9.9% to ₹111.95 crore, reflecting improved operating performance and higher export sales. Despite this top-line growth, the EBITDA margin contracted by 45 basis points to 18.32% from 18.77% in the previous year.

Profit before tax (PBT) before exceptional items rose 35.1% to ₹62.17 crore, supported by a 20.3% decline in finance costs to ₹22.23 crore. This reduction in interest expense was primarily attributable to lower levels of cash credit and working capital loans.

What the Numbers Show

The divergence between robust operational growth and declining bottom-line profitability was driven entirely by non-recurring items. The Company recognized a one-time exceptional loss of ₹332.47 crore during the year. This charge resulted from the reversal of income previously recognized under a transfer of technical know-how arrangement with a Middle East-based customer. Due to regional instability, the customer failed to meet committed timelines, necessitating the reversal. Without this exceptional item, PBT would have grown significantly, highlighting that the core operational engine remains healthy despite the headline profit decline.

Balance Sheet and Capital Structure

The Company strengthened its equity base through the conversion of warrants into equity shares, raising approximately ₹52.71 crore. This capital infusion, alongside debt repayments, reduced the debt-equity ratio to 0.47 times from 0.51 times in FY25.

Net worth expanded by 14.3% to ₹533.00 crore. Cash and cash equivalents surged to ₹37.24 crore from ₹2.60 crore in the prior year, bolstered by operating cash flows of ₹58.08 crore. Trade receivables improved to 140 days of sales from 169 days, indicating better collection efficiency despite revenue growth.

Strategic Developments

During FY26, Bajaj Healthcare continued its transition toward specialized molecules and formulation capabilities. The Company acquired Genrx Pharmaceuticals Private Limited through the insolvency resolution process to strengthen its formulation portfolio, though the facility remains pending tribunal approvals. R&D expenditure doubled to ₹13.15 crore (2.2% of revenue), supporting pipeline development in oncology and complex generics.